Offering a strong focus on regulated industries such as life sciences and tech, the team at Goodwin has a particularly strong focus on strategic merger clearances, successfully preempting Second Requests from the DOJ and FTC, and a successful record in contentious merger cases. The firm continues to be active on high-profile mandates, notably representing iRobot in its proposed $1.7 billion acquisition by Amazon. The practice is jointly led by Andrew Lacy and Arman Oruc. Lacy is an experienced transactional antitrust advisor, while Oruc, who splits his time between DC and Los Angeles, is a key name for merger clearance and antitrust litigation. John Goheen joined the team from Simpson Thacher & Bartlett LLP in January 2023, expanding the firm’s reach across the tech, healthcare, pharma, retail and financial services sectors. Attorneys are based in Washington DC unless otherwise stated.
Key clients
- Concert Pharmaceuticals
- Deliverr, Inc.
- Entrada Therapeutics
- Forma Therapeutics
- Inversago Pharma
- iRobot Corp.
- MiroBio
- Nimbus Therapeutics
- TCR2 Therapeutics Inc.
- Versanis Bio
Work highlights
- Advising iRobot on all antitrust aspects of its proposed $1.7 billion acquisition by Amazon.
- Represented Nimbus Therapeutics in its bet-the-company efforts to navigate through antitrust hurdles to first retain its crown jewel asset against a hostile attempt by Bristol-Myers Squibb (BMS) and subsequently sell it to Takeda for $6 billion in December 2022.
- Advised Entrada Therapeutics, Inc. on its global collaboration with Vertex Pharmaceuticals Incorporated to focus on discovering and developing intracellular Endosomal Escape Vehicle (EEV™) therapeutics for myotonic dystrophy type 1 (DM1).
Practice head
The lawyer(s) leading their teams.
Andrew Lacy, Arman Oruc